HomeCompareTLSYY vs ABBV

TLSYY vs ABBV: Dividend Comparison 2026

TLSYY yields 197.50% · ABBV yields 3.06%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 TLSYY wins by $934849.89M in total portfolio value
10 years
TLSYY
TLSYY
● Live price
197.50%
Share price
$12.48
Annual div
$24.65
5Y div CAGR
25.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$934850.00M
Annual income
$848,360,310,596.63
Full TLSYY calculator →
ABBV
AbbVie Inc.
● Live price
3.06%
Share price
$217.44
Annual div
$6.65
5Y div CAGR
40.6%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$102.3K
Annual income
$24,771.77
Full ABBV calculator →

Portfolio growth — TLSYY vs ABBV

📍 TLSYY pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodTLSYYABBV
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, TLSYY + ABBV cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
TLSYY pays
ABBV pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

TLSYY
Annual income on $10K today (after 15% tax)
$16,787.13/yr
After 10yr DRIP, annual income (after tax)
$721,106,264,007.14/yr
ABBV
Annual income on $10K today (after 15% tax)
$259.96/yr
After 10yr DRIP, annual income (after tax)
$21,056.00/yr
At 15% tax rate, TLSYY beats the other by $721,106,242,951.13/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of TLSYY + ABBV for your $10,000?

TLSYY: 50%ABBV: 50%
100% ABBV50/50100% TLSYY
Portfolio after 10yr
$467425.05M
Annual income
$424,180,167,684.19/yr
Blended yield
90.75%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on ABBV right now

TLSYY
No analyst data
ABBV
Analyst Ratings
27
Buy
12
Hold
1
Sell
Consensus: Buy
Price Target
$256.15
+17.8% upside vs current
Range: $223.00 — $299.00
Altman Z
2.0
Piotroski
8/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

TLSYY buys
0
ABBV buys
0
No recent congressional trades found for TLSYY or ABBV in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricTLSYYABBV
Forward yield197.50%3.06%
Annual dividend / share$24.65$6.65
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR25.6%40.6%
Portfolio after 10y$934850.00M$102.3K
Annual income after 10y$848,360,310,596.63$24,771.77
Total dividends collected$928551.34M$61.0K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: TLSYY vs ABBV ($10,000, DRIP)

YearTLSYY PortfolioTLSYY Income/yrABBV PortfolioABBV Income/yrGap
1← crossover$35,505$24,805.45$11,550$430.00+$24.0KTLSYY
2$141,374$103,382.70$13,472$627.96+$127.9KTLSYY
3$634,470$483,199.95$15,906$926.08+$618.6KTLSYY
4$3,224,396$2,545,513.89$19,071$1,382.55+$3.21MTLSYY
5$18,635,248$15,185,144.25$23,302$2,095.81+$18.61MTLSYY
6$122,957,343$103,017,627.24$29,150$3,237.93+$122.93MTLSYY
7$929,442,721$797,878,364.11$37,536$5,121.41+$929.41MTLSYY
8$8,074,136,158$7,079,632,445.97$50,079$8,338.38+$8074.09MTLSYY
9$80,831,481,487$72,192,155,798.16$69,753$14,065.80+$80831.41MTLSYY
10$934,849,995,787$848,360,310,596.63$102,337$24,771.77+$934849.89MTLSYY

TLSYY vs ABBV: Complete Analysis 2026

TLSYYStock

Telstra Corporation Limited provides telecommunications and information services to businesses, governments, and individuals in Australia and internationally. It operates in four segments: Telstra Consumer and Small Business, Telstra Enterprise, Networks and IT, and Telstra InfraCo. The company offers telecommunication products, services, and solutions across mobiles, fixed and mobile broadband, media, and digital content in prepaid and post-paid services, as well as operates call centers, Telstra shops, and the Telstra dealership network. It also provides network capacity and management, unified communications, cloud, industry solutions, integrated and monitoring services to government and large enterprise customers; builds and manages digital platforms; and provides telecommunication products and services to other carriers, carriage service providers, and internet service providers. In addition, the company operates the fixed passive network infrastructure, including data centers, exchanges, poles, ducts, pits and pipes, fiber network, and mobile towers; provides wholesale customers with access to network infrastructure; provides long-term access to components of infrastructure and network services under the infrastructure services agreement and commercial contracts; and designs and constructs fiber, exchanges, and other infrastructure. The company was formerly known as Australian and Overseas Telecommunications Corporation Limited and changed its name to Telstra Corporation Limited in April 1993. Telstra Corporation Limited was founded in 1901 and is based in Melbourne, Australia.

Full TLSYY Calculator →

ABBVHealthcare

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

Full ABBV Calculator →
📬

Get this TLSYY vs ABBV comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

TLSYY vs SCHDTLSYY vs JEPITLSYY vs OTLSYY vs KOTLSYY vs MAINTLSYY vs JNJTLSYY vs MRKTLSYY vs PFE

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.